



## **Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)**

April 1, 2019

ROCHESTER, N.Y., April 01, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington's disease today announces it will be posting on its website each of the three posters related to the company's anti-SEMA4D technology that were accepted for presentation at the 2019 Annual Meeting of the American Association for Cancer Research (AACR) now underway in Atlanta, Georgia. The Company's website is located at [www.vaccinex.com](http://www.vaccinex.com) and the posters will be available for review under the heading "Investors," sub-heading "Events & Presentations."

### ***Available on the company website beginning April 1, 2019 at 8:00 AM ET:***

Title: "Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors"  
Abstract Number: CT016  
Date and Time: Sunday, March 31, 2019, 1:00 – 5:00 PM ET  
Location: Georgia World Conference Center, Exhibit Hall B, Poster Section 16  
Collaborator: Winship Cancer Institute of Emory University (Investigator Sponsored Clinical Trial)

Title: "Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies"  
Abstract Number: 1545  
Date and Time: Monday, April 1, 2019, 8:00 AM – 12:00 PM ET  
Location: Georgia World Conference Center, Exhibit Hall B, Poster Section 25

### ***Available on the company website beginning April 1, 2019 at 1:00 PM ET:***

Title: "Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC"  
Abstract Number: CT086  
Date and Time: Monday, April 1, 2019, 1:00 – 5:00 PM ET  
Location: Georgia World Conference Center, Exhibit Hall B, Poster Section 16  
Collaborator: Merck KGaA, Darmstadt, Germany

### **About Vaccinex, Inc.**

Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. Vaccinex is based in Rochester, New York.

### **Forward-Looking Statements**

To the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. ("Vaccinex," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "potential," "advance," and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements may involve substantial risks and uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab (VX15/2503), and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in our periodic reports filed with the Securities and Exchange Commission ("SEC") and the other risks and uncertainties described in our prospectus for our initial public offering dated August 9, 2018, filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended.

### **Investor Contact**

Michael Rice  
LifeSci Advisors, LLC  
Phone: (646) 597-6979  
E-mail: [mrice@lifesciadvisors.com](mailto:mrice@lifesciadvisors.com)

### **Media Contact**

Jules Abraham  
JQA Partners, Inc.  
Phone: (917) 885-7378  
E-mail: [jabraham@jqapartners.com](mailto:jabraham@jqapartners.com)



Vaccinex, Inc.